At A Glance
1
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
2
Most recently: . Other Events On December 12, 2025, the Company entered into a Stipulation and Agreement of Compromise, Settlement, and Release (the “Settlement Agreement”) wi (2026-01-15).
—
Market Cap
—
Revenue
—
Net Income
Employees25
Fundamentals
How The Business Makes Money
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001072379
ISINUS66737P6007
CUSIP66737P600
Phone240 497 9024
Address4800 Montgomery Lane, Bethesda, MD, 20814, US
SEC EDGAR